BRCA1 and serous adenocarcinoma: Germline BRCA1/2 pathogenic variants occur in 22.6% of high-grade serous carcinomas (HGSCs), while somatic BRCA1/2 pathogenic variants have been shown in an additional 6–7% of HGSCs [15].